OptiNose Inc
OPTN
Company Profile
Business description
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Contact
1020 Stony Hill Road
Suite 300
YardleyPA19067
USAT: +1 267 364-3500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2024
Employees
132
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
With increased AI spending and hopes of future data center expansion, here’s what we think of Nvidia stock.
stocks
Is this overpriced ASX share too much of a gamble?
We raise our fair value after strong results but shares are pricey.
stocks
ASX players that might thrive under a Trump administration
Recent election results have sent US markets into a record-high rally however implications remain mixed for the Australian share market. See our top ASX picks that could do better under a second Trump administration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,539.00 | 59.10 | 0.70% |
| CAC 40 | 7,309.35 | 2.45 | -0.03% |
| DAX 40 | 19,243.23 | 20.47 | -0.11% |
| Dow JONES (US) | 43,750.86 | 207.33 | -0.47% |
| FTSE 100 | 8,072.96 | 1.77 | 0.02% |
| HKSE | 19,426.34 | 9.47 | -0.05% |
| NASDAQ | 19,107.65 | 123.07 | -0.64% |
| Nikkei 225 | 38,642.91 | 107.21 | 0.28% |
| NZX 50 Index | 12,684.88 | 8.06 | -0.06% |
| S&P 500 | 5,949.17 | 36.21 | -0.60% |
| S&P/ASX 200 | 8,285.20 | 61.20 | 0.74% |
| SSE Composite Index | 3,330.73 | 49.11 | -1.45% |